PRESS RELEASE published on 08/30/2023 at 14:30, 2 years 6 months ago The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
PRESS RELEASE published on 08/28/2023 at 14:30, 2 years 6 months ago Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
PRESS RELEASE published on 08/24/2023 at 13:00, 2 years 6 months ago Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
PRESS RELEASE published on 08/17/2023 at 14:30, 2 years 7 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
PRESS RELEASE published on 08/16/2023 at 14:30, 2 years 7 months ago Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
PRESS RELEASE published on 08/14/2023 at 14:00, 2 years 7 months ago Jaguar Health Reports Second Quarter 2023 Financial Results
PRESS RELEASE published on 08/10/2023 at 14:30, 2 years 7 months ago Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
PRESS RELEASE published on 08/09/2023 at 14:30, 2 years 7 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
PRESS RELEASE published on 08/08/2023 at 14:30, 2 years 7 months ago Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
PRESS RELEASE published on 08/07/2023 at 14:30, 2 years 7 months ago Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
Published on 03/19/2026 at 07:30, 20 minutes ago Tocvan Drone Magnetic Data Strengthens Gold-Silver Targets Across Gran Pilar; Identifies Broad Zones for Expansion Potential
Published on 03/19/2026 at 06:35, 1 hour 15 minutes ago Golden Lake Announces Securityholder Approval of Arrangement with McEwen Inc.
Published on 03/19/2026 at 01:05, 6 hours 45 minutes ago Prospect Ridge Announces Closing of Flow-Through Share Private Placement
Published on 03/18/2026 at 23:45, 8 hours 5 minutes ago Orogen Royalties Announces Private Placement Update
Published on 03/18/2026 at 21:00, 10 hours 50 minutes ago PLDT's Smart Selects Amdocs to Transform Retail Operations with AI-Powered Store Genie
Published on 03/19/2026 at 07:35, 15 minutes ago Lenzing advances its transformation: Higher EBITDA, stronger free cash flow and more than EUR 200 million in cost savings
Published on 03/19/2026 at 07:30, 20 minutes ago Additional Phase 2 Data of AL-S Pharma’s Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification and Prolonged Survival in ALS
Published on 03/19/2026 at 07:30, 20 minutes ago The Nordex Group receives orders totaling 54 MW from Prowind in Germany
Published on 03/19/2026 at 07:30, 20 minutes ago Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
Published on 03/19/2026 at 07:30, 20 minutes ago SGL Carbon: Restructuring ensures earnings forecast and creates basis for new growth
Published on 03/19/2026 at 07:00, 50 minutes ago bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe
Published on 03/18/2026 at 19:41, 12 hours 8 minutes ago Covivio - Conditions of availability of the 2025 Universal Registration Document
Published on 03/18/2026 at 18:00, 13 hours 50 minutes ago Deezer achieves profitability in FY25 as strategy delivers tangible results
Published on 03/18/2026 at 17:45, 14 hours 5 minutes ago Infotel : 2025 full-year results. Launch of a new Infotel 2030 strategic plan. Revenue target of €500 million by 2030.
